Johnson & Johnson chief executive Joaquin Duato told investors the firm aims to cure select cancers and convert others into chronic conditions within the next decade. He outlined a strategy to become the No. 1 oncology company by 2030, leveraging AI-driven drug discovery and a pipeline of new platforms acquired through recent deals. The declaration follows a broader industry shift toward precision medicine and immunotherapy.

Last week the group announced a $1 billion cash purchase of biotech Firefly Bio, adding a novel antibody‑drug conjugate platform to its oncology arsenal. The acquisition is expected to mature over several years, expanding J&J’s reach beyond its existing immuno‑oncology assets and sharpening its competitive edge against rivals such as Roche and Merck. Integration plans include joint clinical trials and manufacturing capacity to speed time‑to‑market.

Duato emphasized that AI already accelerates R&D, though its impact on earnings remains unproven. By stacking organic innovation with targeted buyouts, the company hopes to boost pipeline productivity and capture higher market share in high‑margin cancer therapies. Analysts will watch earnings for signs AI translates into cost savings.